A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT05547490

IM011-206

Details and patient eligibility

About

The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical needs and disease burden in real-world setting in China.

Enrollment: 3,506 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of moderate-to-severe plaque PsO either confirmed by a dermatologist or meeting criteria of: BSA ≥ 3% or PASI ≥ 3 or Dermatology Life Quality Index (DLQI) ≥ 6.

Exclusion criteria

• Participating in Randomized controlled trial (RCT) between 1st January 2018 and 31st December 2021, if there was any.
• Diagnosis of erythrodermic psoriasis, pustular psoriasis or guttate psoriasis.

Trial design

3,506 participants in 1 patient group

Moderate-to-severe Plaque PsO

Description:

Participants experiencing moderate-to-severe plaque PsO, who have had at least one clinical visit.